✦ LIBER ✦

Rember: Issues in design of a phase 3 disease modifying clinical trial of Tau aggregation inhibitor therapy in Alzheimer's disease

✍ Scribed by Claude Wischik

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

TauRx global phase 3 trial in Alzheimer'

✍ Wischik, Claude M.; Harrington, C.R.; Storey, J.M.D. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 50 KB

O3-04-07: Tau aggregation inhibitor (TAI

✍ Claude M. Wischik; Peter Bentham; Damon J. Wischik; Kwang Meng Seng 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 54 KB

Challenges in the conduct of disease-mod

✍ C. Wischik; R. Staff 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 98 KB

Neuroimaging biomarkers for clinical tri

✍ Dickerson, Bradford C. ;Sperling, Reisa A. 📂 Article 📅 2005 🏛 American Society for Experimental NeuroTherapeutic 🌐 English ⚖ 273 KB

P4-347: Tau aggregation inhibitor (TAI)

✍ Staff, Roger T.; Ahearn, Trevor S.; Murray, Alison D.; Bentham, Peter; Seng, Kwa 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 104 KB

P4-343: Omega 3 fatty acids and Alzheime

✍ Quinn, Joseph F.; Raman, Rema; Thomas, Ronald; Ernstrom, Karin; Yurko-Mauro, Kar 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 53 KB